Treatment opportunities for refractory immune thrombocytopenia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study2024 · 23 citations
2. 2Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia2019 · 73 citations
3. 3Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study2022 · 88 citations
4. 4Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations2012 · 24 citations
5. 5Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group2008 · 2,712 citations